Chapter 25 The pharmaceutical industry

Handbook of Health Economics

Volumn 1, Issue PART B, 2000, Pages 1297-1336

  Scherer, F M ^a  

^a HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956767348     PISSN: 15740064     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1574-0064(00)80038-4     Document Type: Review

References (109)

1. Ager B. Patents, pharmaceuticals and generics. Eurohealth 2 (1997) 35-36
2. Anis A.H., and Wen Q. Price regulation of pharmaceuticals in Canada. Journal of Health Economics 17 (1998) 21-38
3. Bakke O.M., Manochia M., de Abajo F., Kaitin K.I., and Lasagna L. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993. Clinical Pharmacology and Therapeutics 58 (1995) 108-117
4. Ballance R., Pogany J., and Forstner H. The World's Pharmaceutical Industries: An International Perspective on Innovation, Competition and Policy (1992), Edward Elgar for United Nations Industrial Development Organization, Amsterdam
5. Bangemann M. Completing the single pharmaceutical market. Eurohealth 3 1 (1997) 22-23
6. Beales J.J. New uses for old drugs. In: Helms R.B. (Ed). Competitive Strategies in the Pharmaceutical Industry (1996), AEI Press, Hants, UK 281-305
7. Berndt E.R., Bui L., Reiley D.R., and Urban G.L. Information, marketing, and pricing in the U.S. antiulcer drug market. American Economic Review 85 2 (1995) 100-105
8. Bond R.S., and Lean D.F. Sales, Promotion, and Product Differentiation in Two Prescription Drug Markets (1977), Federal Trade Commission, Washington
9. Boston Consulting Group. The Changing Environment for U.S. Pharmaceuticals (Boston) (1993)
10. Caves R.E., Whinston M., and Hurwitz M. Patent expiration, entry, and competition in the U.S. pharmaceutical industry. Brookings Papers on Economic Activity: Microeconomics 1991 (1991) 1-48
11. Cockburn I., and Henderson R. Absorptive capacity, coauthoring behavior, and the organization of research in drug discovery. Journal of Industrial Economics 46 (1998) 157-182
12. Cohen W.M., Nelson R.R., and Walsh J. Appropriability conditions and why firms patent and why they do not in the American manufacturing sector. Working Paper (1997), Carnegie-Mellon University, Washington
13. Comanor W.S. The political economy of the pharmaceutical industry. Journal of Economic Literature 24 (1986) 1178-1217
14. Cooper J.D. The sources of innovation. In: Cooper J.D. (Ed). The Economics of Drug Innovation (1970), American University, Pittsburgh 41-62
15. Danzon P.M. Pharmaceutical Price Regulation (1997), AEI Press, Washington
16. Deardorff A.V. Welfare effects of global patent protection. Economica 59 (1992) 35-51
17. DiMasi J.A., Hansen R.W., Grabowski H.G., and Lasagna L. Cost of innovation in the pharmaceutical industry. Journal of Health Economics 10 (1991) 107-142
18. DiMasi J.A., Seibring M., and Lasagna L. New drug development in the United States from 1963 to 1992. Clinical Pharmacology and Therapeutics 55 (1994) 609-622
19. Dorfman R., and Steiner P.O. Optimal advertising and optimal quality. American Economic Review 44 (1954) 826-836
20. Dranove D. Medicaid drug formulary restrictions. Journal of Law and Economics 32 (1989) 143-162
21. Ellison S.F., Cockburn I., Griliches Z., and Hausman J. Characteristics of demand for pharmaceutical products: An examination of four cephalosporins. RAND Journal of Economics 28 (1997) 427-446
22. Fattore G. Pharmaceutical policy in Italy 1992-1995. Eurohealth 2 (1996) 34-35
23. Frank R.G., and Salkever D.S. Pricing, patent loss and the market for pharmaceuticals. Southern Economic Journal 59 (1992) 165-179
24. Frank R.G., and Salkever D.S. Generic entry and the pricing of pharmaceuticals. Journal of Economics and Management Strategy 6 (1997) 75-90
25. Gambardella A. Science and Innovation: The US Pharmaceutical Industry During the 1980s (1995), Cambridge University Press, Washington
26. (Santa Monica, CA). Garber S. Product liability and the economics of pharmaceuticals and medical devices. RAND Corporation Report R-4285-ICJ (1993)
27. Chapter 13. Glied S. Managed care. In: Culyer A.J., and Newhouse J.P. (Eds). Handbook of Health Economics (2000), Elsevier, Cambridge, UK
28. Gorecki P.K. The importance of being first: The case of prescription drugs in Canada. International Journal of Industrial Organization 4 (1986) 371-396
29. Grabowski H.G. Drug Regulation and Innovation (1976), American Enterprise Institute, Amsterdam
30. Grabowski H.G., and Vernon J.M. The Regulation of Pharmaceuticals (1983), American Enterprise Institute, Washington
31. Grabowski H.G., and Vernon J.M. A new look at the returns and risks to pharmaceutical R&D. Management Science 36 (1990) 804-821
32. Grabowski H.G., and Vernon J.M. Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 drug act. Journal of Law and Economics 35 (1992) 331-350
33. Grabowski H.G., and Vernon J.M. Returns on new drug introductions in the 1980s. Journal of Health Economics 13 (1994) 383-406
34. Grabowski H.G., and Vernon J.M. Longer patents for increased generic competition in the US. PharmacoEconomics 10 Supplement 2 (1996) 110-123
35. Grabowski H.G., Vernon J.M., and Thomas L.G. Estimating the effects of regulation on innovation: An international comparative analysis. Journal of Law and Economics 21 (1978) 133-163
36. Griliches Z., and Cockburn I. Generics and new goods in pharmaceutical price indexes. Working Paper No. 4272 (1993), National Bureau of Economic Research, Washington
37. Henderson R., and Cockburn I. Scale, scope, and spillovers: The determinants of research productivity in drug discovery. RAND Journal of Economics 27 (1996) 32-59
38. Heppell S. The new European system for regulating medicinal products. Eurohealth 2 (1996) 28-29
39. Holmes J., and Dunning J. Factors influencing the location of multinational investment in the pharmaceutical industry. In: Towse A. (Ed). Industrial Policy and the Pharmaceutical Industry (1995), Office of Health Economics 92-105
40. IIT Research Institute. Technology in Retrospect and Critical Events in Science (1968), Illinois Institute of Technology, London
41. Ikegami N., Ikeda S., and Kawai H. Why medical care costs in Japan have increased despite declining prices of pharmaceuticals. PharmacoEconomics 14 Supplement 1 (1998) 97-105
42. Kaitin K.I. The new drug approvals of 1993, 1994, and 1995. American Journal of Therapeutics 4 (1997) 46-54
43. Kitch E.W. The patent system and the new drug application. In: Landau R.L. (Ed). Regulating New Drugs (1973), University of Chicago Center for Policy Study, Chicago 81-108
44. Kopp S.W., and Sheffer M.J. The effect of direct-to-consumer advertising of prescription drugs on retail gross margins. Journal of Public Policy and Marketing 16 (1997) 270-276
45. Lanjouw J.O. The introduction of pharmaceutical product patents in India. Discussion Paper No. 775 (1997), Yale University Economic Growth Center
46. Leibowitz A., Manning W.G., and Newhouse J.P. The demand for prescription drugs as a function of cost sharing. Social Science Medicine 21 (1985) 251-277
47. Levin R.C., Klevorick A.K., Nelson R.R., and Winter S.G. Appropriating the returns from industrial research and development. Brookings Papers on Economic Activity 3 (1987) 783-821
48. Lichtenberg F.R. The effect of pharmaceutical utilization and innovation on hospitalization and mortality. Working Paper No. 5418 (1996), National Bureau of Economic Research
49. Lichtenberg F.R. Pharmaceutical innovation, mortality reduction, and economic growth. Working Paper No. 6569 (1998), National Bureau of Economic Research, Cambridge, MA
50. Lu J.L., and Comanor W.S. Strategic pricing of new pharmaceuticals. Review of Economics and Statistics 80 (1998) 108-118
51. Mann C.C., and Plummer M.L. The Aspirin Wars (1991), Harvard Business School Press, Cambridge, MA
52. Manning R.L. Changing rules in tort law and the market for childhood vaccines. Journal of Law and Economics 37 (1994) 247-275
53. Manning R.L. Products liability and prescription drug prices in Canada and the United States. Journal of Law and Economics 49 (1997) 203-244
54. Mansfield E. Comment. In: Cooper J.D. (Ed). The Economics of Drug Innovation (1970), American University, Boston 149-154
55. Mansfield E. Academic research underlying industrial innovations. Review of Economics and Statistics 77 (1995) 55-65
56. Masson A., and Steiner R.L. Generic substitution and prescription drug prices. Staff Report (1985), Federal Trade Commission, Washington
57. McFetridge D.G. Intellectual property rights and the location of innovative activity: The Canadian experience. Working Paper (1997), Carleton University, Washington
58. McRae J.J., and Tapon F. Some empirical evidence on post-patent barriers to entry in the Canadian pharmaceutical industry. Journal of Health Economics 4 (1985) 43-61
59. Moore W.J., and Newman R. Drug formulary restrictions as a cost-containment policy in Medicaid programs. Journal of Law and Economics 36 (1993) 71-114
60. Morton F.S. The strategic response by pharmaceutical firms to the Medicaid most-favored-customer rules. RAND Journal of Economics 28 (1997) 269-290
61. Morton F.S. The objectives of the FDA's Office of Generic Drugs. Working Paper No. 6143 (1997), National Bureau of Economic Research, Ottawa
62. Neary I. Japanese industrial policy and the pharmaceutical industry. In: Towse A. (Ed). Industrial Policy and the Pharmaceutical Industry (1995), Office of Health Economics 12-25
63. Newhouse J.P., and the Insurance Experiment Group. Free for All? Lessons from the RAND Health Insurance Experiment (1993), Harvard University Press, London
64. Peltzman S. An evaluation of consumer protection legislation: The 1962 drug amendments. Journal of Political Economy 81 (1973) 1049-1091
65. Peltzman S. The health effects of mandatory prescriptions. Journal of Law and Economics 30 (1987) 207-238
66. Perry G. Generic medicines: How to ensure their effective contribution to health care. Eurohealth 2 (1996) 32-34
67. PhRMA. Industry Profile: 1997 (1997), Pharmaceutical Research and Manufacturers of America, Cambridge
68. PhRMA. Industry Profile: 1998 (1998), Pharmaceutical Research and Manufacturers of America, Washington
69. Rizzo J.A. Advertising and competition in the ethical pharmaceutical industry: The case of antihypertensive drugs. Working Paper (1997), Yale University, Washington
70. Robinson W.T., Kalyanaram G., and Urban G. First-mover advantages from pioneering new markets: A survey of the empirical evidence. Review of Industrial Organization 9 (1994) 1-24
71. Ryan M.P. Knowledge Diplomacy: Global Competition and the Politics of Intellectual Property (1998), Brookings
72. Santoro M. Pfizer: Protecting intellectual property in a global marketplace. Case Study N9-392-072 (1992), Harvard Business School, Washington
73. Schachtel B.P. Sensible and sensitive clinical trials in the evaluation of over-the-counter drugs. In: Shulman S.R. (Ed). Moving Prescription Drugs to the Over-the-Counter Market (1994), Tufts University Human Nutrition Center, Boston
74. Scherer F.M. US industrial Policy in the pharmaceutical industry. In: Towse A. (Ed). Industrial Policy and the Pharmaceutical Industry (1995), Office of Health Economics, Boston 26-39
75. Scherer F.M. Industry Structure, Strategy, and Public Policy (1996), Harper-Collins, London
76. Scherer F.M. How U.S. antitrust can go astray. International Journal of the Economics of Business 4 (1997) 239-256
77. Scherer F.M. The size distribution of profits from innovation. Annales d'Economie et de Statistique 49/50 (1998) 496-516
78. Scherer F.M., and Ross D.R. Industrial Market Structure and Economic Performance. 3rd edn. (1990), Houghton-Mifflin, New York
79. Scherer F.M., and Weisburst S. Economic effects of strengthening pharmaceutical patent protection in Italy. International Review of Industrial Property and Copyright Law 26 (1995) 1009-1024
80. Schöffski O. Consequences of implementing a drug budget for office-based physicians in Germany. PharmacoEconomics 10 Supplement 2 (1996) 37-47
81. Schwartzman D. Innovation in the Pharmaceutical Industry (1976), Johns Hopkins University Press, Boston
82. Schwartzman D. Has pharmaceutical research become more scientific?. Review of Industrial Organization 11 (1997) 841-851
83. Shulman S.R., and Kaitin K.I. The prescription drug user fee act of 1992. PharmacoEconomics 9 2 (1996) 121-133
84. In: Shulman S.R., and Lasagna L. (Eds). Pricing and Reimbursement of Pharmaceuticals: An Evaluation of Cost-Containment Strategies, Symposium proceedings. PharmacoEconomics 6 (1994)
85. Soumerai S.B., Ross-Degnan D., Ahorn J., McLaughlin T.J., and Choodnovskiy I. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. New England Journal of Medicine 325 (1991) 1072-1077
86. Steiner R.L. The inverse association between the margins of manufacturers and retailers. Review of Industrial Organization 8 (1993) 717-740
87. Task Force on Prescription Drugs. The Drug Makers and the Drug Distributors (1968), US Department of Health, Education and Welfare, Baltimore
88. Task Force on Prescription Drugs. Final Report (1969), US Department of Health, Education and Welfare, Washington
89. Temin P. The origin of compulsory drug prescriptions. Journal of Law and Economics 22 (1979) 91-105
90. Temin P. Technology, regulation, and market structure in the modern pharmaceutical industry. Bell Journal of Economics 10 (1979) 429-446
91. Thomas L.G. Industrial policy and international competitiveness in the pharmaceutical industry. In: Helms R.B. (Ed). Competitive Strategies in the Pharmaceutical Industry (1996), AEI Press, Washington 107-129
92. Toole A.A. The impact of federally funded basic research on industrial innovation: Evidence from the pharmaceutical industry. Working Paper (1997), Christensen Associates, Washington
93. Tufts University Center for the Study of Drug Development. Tufts CSDD testifies before Canadian Parliamentary Committee about U.S. experience with patent extension. Tufts CSDD Newsletter 22 (1997) 1-2
94. US Bureau of the Census. 1987 Census of Manufactures, Concentration Ratios in Manufacturing, MC87-S-6 (1992), USGPO, Madison, WI
95. US Bureau of the Census. Statistical Abstract of the United States: 1996 (1996), USGPO, Washington
96. US Bureau of the Census. 1995 Annual Survey of Manufactures, Value of Product Shipments, M95-(AS)-2 (1997), USGPO, Washington
97. US Congressional Budget Office. How the Medicaid Rebate on Prescription Drugs Affects Pricing in the Pharmaceutical Industry (1996), CBO Papers, Washington
98. US Congressional Budget Office. How Increased Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry (Washington) (1998)
99. US Federal Trade Commission. Economic Report on Antibiotics Manufacture (1958), USGPO, Washington
100. US Federal Trade Commission. Statistical Report: Annual Line of Business Report: 1977 (Washington) (1985)
101. US House of Representatives, Committee on Science and Technology. Report, The Food and Drug Administration's Process for Approving New Drugs (1980), USGPO, Washington
102. US National Science Board. Science and Engineering Indicators: 1998 (1998), USGPO, Washington
103. NSF 96-304 (Washington). US National Science Foundation. Research and Development in Industry: 1993 (1996)
104. US Office of Technology Assessment. Federal Policies and the Medical Devices Industry (1984), USGPO, Washington
105. US Office of Technology Assessment. Pharmaceutical R&D: Costs, Risks and Rewards (1993), USGPO, Washington
106. Wardell W., and Lasagna L. Regulation and Drug Development (1975), American Enterprise Institute, Washington
107. Weintraub M. OTC drugs: Definitional and methodologic aspects. In: Shulman S.R. (Ed). Moving Prescription Drugs to the Over-the-Counter Market (1994), Tufts University Human Nutrition Research Center, Washington
108. Yarrow G. CED and EC member state industrial policy and the pharmaceutical industry. In: Towse A. (Ed). Industrial Policy and the Pharmaceutical Industry (1995), Office of Health Economics, Boston
109. New York Times, August 5. Zuger A. Drug companies' sales pitch: Ask your doctor (1997) C1